This study aims to evaluate the effect on killing efficacy of the intracellular trafficking patterns of a-particle emitters by using different radionuclide carriers in the setting of targeted antivascular a-radiotherapy. Nanocarriers (lipid vesicles) targeted to the prostate-specific membrane antigen (PSMA), which is unique to human neovasculature for a variety of solid tumors, were loaded with the a-particle generator actinium-225 and were compared with a PSMA-targeted radiolabeled antibody. Actinium-225 emits a total of four a-particles per decay, providing highly lethal and localized irradiation of targeted cells with minimal exposure to surrounding healthy tissues. Lipid vesicles were derivatized with two types of PSMA-targeting ligands: a fully human PSMA antibody (mAb) and a urea-based, low-molecular-weight agent. Target selectivity and extent of internalization were evaluated on monolayers of human endothelial cells (HUVEC) induced to express PSMA in static incubation conditions and in a flow field. Both types of radiolabeled PSMA-targeted vesicles exhibit similar killing efficacy, which is greater than the efficacy of the radiolabeled control mAb when compared on the basis of delivered radioactivity per cell. Fluorescence confocal microscopy demonstrates that targeted vesicles localize closer to the nucleus, unlike antibodies which localize near the plasma membrane. In addition, targeted vesicles cause larger numbers of dsDNAs per nucleus of treated cells compared with the radiolabeled mAb. These findings demonstrate that radionuclide carriers, such as PSMA-targeted lipid-nanocarriers, which localize close to the nucleus, increase the probability of a-particle trajectories crossing the nuclei, and, therefore, enhance the killing efficacy of a-particle emitters. Mol Cancer Ther; 15(1); 106-13. Ó2015 AACR.
Introduction
The importance of antivascular therapy in the adjuvant treatment of cancer is well recognized (1). Critical prerequisites in this scenario, however, include the selective targeting of the tumor vasculature and the targeted delivery of highly lethal therapeutics. Among numerous antivascular agents developed and studied (1-3), a-particle emitters are identified for their exceptional suitability (3, 4) . This is due to the high linear energy transfer (LET; of the order of 80 keV/mm) and short range (50-100 mm) of a-particles resulting in highly lethal and localized irradiation of the tumor vasculature. To increase the killing efficacy of delivered radioac-tivity further, although not traditionally considered for a-particle emitters (5) , different radionuclide carriers could be evaluated to explore potentially favorable spatiotemporal intracellular distributions (intracellular trafficking) of the a-emitters which could increase the probability of nuclear hits.
The design of preclinical studies, which aim to evaluate experimental neovasculature-targeting constructs, faces at least two major technical limitations. Human tumor endothelial cells expressing human antigens of targeting interest are practically still not available in culture (6) , and in animal models the neovasculature and its antigens are of host-origin. To emulate tumor endothelium analogues in vitro, we utilize a parallel-plate flow chamber with a controlled flow field containing the targeted therapeutics and with walls coated with monolayers of model human endothelial cells (HUVEC) induced to express the prostate-specific membrane antigen (PSMA). PSMA is a homodimeric type II integral membrane glycoprotein, is selectively found in the neovasculature of patients with several PSMA-negative tumors, and is absent in the healthy endothelium (7, 8) .
In this study, we hypothesize that the patterns of intracellular trafficking of delivered a-particle emitters may significantly affect the efficacy of the delivered radioactivity. In order to explore this hypothesis, we designed lipid-based nanocarriers (lipid vesicles) loaded with the a-particle generator Actinium-225 ( 225 Ac) and labeled the vesicles with two different types of PSMA-targeting ligands, which appear to target similar epitopes of PSMA: a fully human PSMA antibody (mAb), and a urea-based low-molecularweight agent (9) . The therapeutic generator 225 Ac emits a total of four a-particles per decay (10) . We evaluate both vesicle constructs and compare with the radiolabeled antibody in terms of targeting selectivity and killing efficacy, which are then compared with the intracellular trafficking patterns and any resulting dsDNA for all constructs.
Materials and Methods

Materials
The
were purchased from Avanti Polar Lipids and were used without further purification (all lipids at purity > 99%). 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and p-SCN-Bn-DOTA (DOTA-SCN) were purchased from Macrocyclics. Cholesterol (Chol), PBS, Sephadex G-50, Sepharose 4B, sodium carbonate, tetramethylammonium acetate (TMAA), sodium chloride (NaCl), glycine, sucrose, diethylenetriaminepentaacetic acid (DTPA), calcium ionophore A23187, dithiothreitol (DTT), 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), Endothelial Cell Growth Supplement (ECGS), heparin sodium salt, and N,N-dimethylformamide (DMF) were purchased from Sigma-Aldrich Chemical. Ethylenediaminetetraaceticd acid, disodium salt Dihydrate (EDTA) was purchased from Fisher Scientific. FBS was purchased from Omega Scientific. CellTiter 96 Non-Radioactive cell proliferation assay (MTT) was purchased from Promega Corporation. Matrigel was purchased from BD Biosciences. 10DG and PD10 desalting columns were obtained from BioRad. For isotype control antibody, a human IgG1K (catalog number 0151K-01) was purchased from Southern Biotech. Actinium-225 ( 225 Ac, actinium chloride) was provided by the Institute for Transuranium Elements.
For the synthesis of lysine-glutamate urea conjugated to the free polymer chain(s) of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG(2000)), a solution of N-hydroxysuccinimide ester of suberate lysine-glutamate urea (ref. 11; 5 mg, 8.98 mmol, in 500 mL DMF) was added to DSPE-PEG(2000) (10 mg, 3.6 mmol in 900 mL DMF) followed by N,N-diisopropylethylamine (DIEA; 3 mL, 18 mmol). The reaction mixture was stirred at room temperature for 2 hours, and was then concentrated under reduced pressure at approximately 40 C. The semi-solid residue thus obtained was washed with 5 Â 1 mL 80/20 water/ acetonitrile solution to remove unreacted lysine-glutamate urea. The colorless product was dried under high vacuum for 20 hours and was used for experiments. The synthesis yield was approximately 90% and with m/Z: 1594.5 [Mþ1]2þ by Elec-troSpray Mass Spectrometry. The molecular structure of the functionalized lipid with a nonactive analogue (negative control) of the urea ligand is shown in Supplementary Fig. S1C . The targeting urea molecule is a small molecule (not a peptide), therefore, for the design of the negative control, a linker was attached to the lipid.
Lipid vesicle preparation and loading of constructs with 225 Ac
Vesicles composed of 21PC:Chol:DSPE-PEG:DPPE-Rhodamine at the mole ratio of 66.0:28.3:4.7:1.0 were formed using the thin film hydration method. All vesicles were labeled with 1 mole% of DPPE-Rhodamine lipid. For all targeted vesicles, either 0.5 mole% of the lysine-glutamate urea-based lipid (urea-lipid ref. 9) conjugate (resulting in a mole ratio of 65.7:28.2:4.7:0.9:0.5 21PC:chol:DSPE-PEG:DPPE-Rhodamine:lipid-urea) was included during the vesicle preparation step or the PSMA targeting antibody (Progenics Pharmaceuticals, Inc.) was conjugated on the PDP-modified free ends of PEG-chains using standard clickchemistry (12) . Vesicles were suspended in HEPES buffer (20 mmol/L HEPES, 250 mmol/L sucrose at pH ¼ 7.4) and were prepared to encapsulate citrate buffer (140 mmol/L citrate buffer with 5 mg/mL DOTA and 2.1 mg/mL ascorbic acid, pH 5.0). Vesicle size was measured using a Zetasizer NanoSeries (Malvern Instruments Ltd).
To load 225 Ac in vesicles, 1 mL (5 mmol/L total lipid) of vesicle suspension was incubated for 60 minutes at 80 C in a dry heating bath with 0.08 mL of a solution containing the following: 0.03 mL of 225 Actinium in 3 mmol/L HCl combined with 0.05 mL suspension of A23187 in an equimolar mixture of ethanol and water and at a final concentration in the vesicle suspension of 0.37 mg A23187/mL. After one hour of incubation, 0.05 mL of 10 mmol/L DTPA was added to the vesicle suspension to complex any unentrapped 225 Ac or 225 Ac adsorbed on the vesicle surface (12) . Purification and determination of loading efficiency were performed using size exclusion chromatography with a 10-cm Sephadex G-50 column eluted with PBS (pH ¼ 7.4, 300 mOsm) and by measuring radioactivity associated with the eluted vesicle suspension.
Antibody radiolabeling was performed using a two-step process which involved radiolabeling of a isothiocyanate-functionalized derivative of DOTA at 60 C in 2 mol/L tetramethylammonium acetate followed by labeling of antibodies with the radioactive chelate at lower temperature (13) . The final eluted sample was evaluated for radiochemical purity and radiolabeling efficiency using ITLC.
Characterization of targeted constructs
Immunoreactivity of the urea-based ligand (11) and of the antibody (before and) after conjugation to vesicles was evaluated on the stably PSMA-positive LnCaP cell line in monolayers using antigens in excess of the ligands. The apparent-binding affinity K D of targeted vesicles was evaluated on fixed, but not permeabilized, PSMA þ HUVEC by measuring the cell-associated radioactivity on cells incubated with targeted 225 Ac-loaded vesicles using serial dilutions, and on cells incubated in addition with 50 times excess of targeted non-radiolabeled vesicles (14) .
Cell lines and preparation of cell conditioned media
All cell lines (HUVEC and MDA-MB-231) were acquired from ATCC in 2013 and 2014, and were cultured in media suggested by ATCC supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin in an incubator at 37 C and 5% CO 2 . F12-K medium, used for HUVEC, was additionally supplemented with Heparin sodium salt (0.1 mg/mL) and ECGS (0.03 mg/mL). ATCC uses the following characterization tests: post-freeze viability, confirmation that cells are adherent, cell morphology, mycoplasma contamination, confirmation that cells are human in origin, and confirmation that cells do not contain pathogenic viruses. Cell conditioned media (CCM) were generated from the MDA-MB-231 breast cancer cell line (15) .
Induction of PSMA expression on HUVEC cells
HUVEC cells were plated on Matrigel at a density of 10 6 cells per mL of CCM and were incubated in a humidified incubator at 37 C and 5% CO 2 for 18 hours according to a published method (15) . Upon completion of incubation, PSMA expression was evaluated fluorometrically by immunofluorescence measured in a FACS Calibur flow cytometer and by Western blot analysis.
In particular, suspensions of fixed (with paraformaldehyde) HUVEC which previously had been carefully scraped and had been separated from Matrigel by centrifugation (277 Â g for 5 minutes) were incubated for 60 minutes with a primary human anti-PSMA mouse monoclonal antibody (LifeSpan BioSciences, Inc.) followed by an additional 60-minute incubation with a FITC-labeled goat anti-mouse Fc secondary antibody (Jackson ImmunoResearch Laboratories). PSMA-positive LnCaP cells and PSMA-negative (not activated) HUVEC cells were also evaluated.
For Western blot analysis, cell lysate proteins were processed through SDS-PAGE under reducing conditions, followed by transfer onto nitrocellulose membrane. Membrane was blocked with 5% non-fat dry milk in TBST (20 mmol/L Tris, 150 mmol/L NaCl, 0.05% Tween-20) for 1 hour at room temperature, probed with primary mouse anti-PSMA antibody (ab19071, Abcam) in 0.5% milk in TBST for 1 hour at room temperature, and washed three times with TBST. The membrane was then probed with goat antimouse IgG-HRP conjugate (A24518, Life Technologies) for 1 hour at room temperature and then washed three times with TBST. Color was developed by adding HRP substrate (1706431, Bio-Rad) and incubating for 30 minutes.
Cell association of delivered radioactivity and cell viability studies
Binding of constructs under flow was determined using a rectangular parallel plate flow chamber (Glycotech). For PSMA þ HUVEC, studies were initiated by introduction of 225 Ac-loaded constructs in CCM at a lipid concentration of 83.33 mmol/L and activity of 37 kBq/mL at a constant flow rate of 0.1 mL/minute using a PHD Ultra Syringe Pump (Harvard Apparatus) at 37 C and 5% CO 2 . Parallel experiments were performed under static conditions. For studies on PSMA À HUVEC, cells were directly plated on fibronectin-covered slides in regular F12-K media as also were all constructs. At the end of incubation, cells were washed twice using ice cold PBS and were resuspended in F12-K media with 10% FBS, were counted using a hemocytometer, and were then used to determine (i) the cell associated radioactivity by counting the g-emissions of Bismuth-213 upon reaching secular equilibrium; (ii) the extent of cell internalized radioactivity; and (iii) the viability of cells using the MTT assay. The extent of 225 Ac retention by all constructs was measured on a fraction of cell-exposed suspension using size exclusion chromatography.
Intracellular localization of constructs imaged by confocal microscopy
HUVECs were incubated under static conditions with nonradioactive, rhodamine-tagged vesicles or FITC-labeled antibody in the presence (see below) or absence of endocytosis inhibitors. After completion of incubation (6 hours), HUVECs were fixed with paraformaldehyde (4% in PBS for 10 minutes) before Hoechst 33342 staining, and then washed (3x) with PBS. Monolayers were imaged using a Leica TCS SP2 confocal laser scanning microscope under a 40Â and an oil immersion 100Â objective. For quantitative intracellular distributions of all constructs, a dilation protocol was applied. The fluorescence image of each cell nucleus was thresholded to yield a binary space that represented the boundaries of the nucleus. A circular morphologic structuring element was used to follow the edges of the thresholded nucleus image forming multiple concentric rings that expanded outward from the nucleus to the plasma membrane of the cell. The sum of pixel intensities within each ring was normalized to the sum of pixel intensities over the entire cell and graphed relative to the distance from the nucleus edge.
Characterization of cellular uptake mechanism
PSMA þ HUVECs were incubated for 30 minutes with chlorpromazine (10 mg/mL) or with genistein (100 mg/mL) before incubation with fluorescently labeled constructs. Upon completion of incubation, cells were washed and evaluated for fluorescence uptake using flow cytometry. In presaturation experiments, cells were incubated for 60 minutes with 1,000Â excess of free PSMA antibody (25 mg/mL) or the free lysine glutamate urea agent (0.1 mg/mL; ref. 16 ) before incubation with fluorescently labeled constructs.
Immunofluorescent staining of g-H2AX foci
Phosphorylation of histone g-H2AX was imaged by immunofluorescence using the same confocal microscope as above. The g-H2AX foci were treated as biomarkers of dsDNA breaks induced by the emitted a-particles. Upon completion of incubation with radioactivity, cells were washed and fixed in 4% paraformaldehyde for 10 minutes at room temperature, and were permeabilized using 0.1% Triton X-100 in PBS. After permeabilizing for 5 minutes at room temperature, cells were stained for g-H2AX using OxiSelect DNA Double Strand Break kit from CellBioLabs per kit instructions.
Statistical analysis
Results are reported as the arithmetic mean of n independent measurements AE the SD. The Student t test was used to calculate significant differences in killing efficacy between the various constructs. P values less than 0.01 are considered to be significant.
Results
Lipid vesicle characterization
The average vesicle size was 107 AE 5 nm (n ¼ 12); PDI ¼ 0.06 AE 0.04 (n ¼ 12). Antibody conjugation resulted in 31 AE 9 antibodies per vesicle (n ¼ 4), and the optimization studies on urea-based targeted vesicles indicated that a density of approximately 368 urea-based ligands per vesicle exhibit best uptake ( Supplementary  Fig. S1 ). The immunoreactivity of the radiolabeled antibody was 88.6 AE 0.8%. The apparent immunoreactivity of the antibodylabeled vesicles was 18.1 AE 1.5% (n ¼ 3), and of the urea-labeled vesicles was 15.8 AE 1.6% (n ¼ 3). Targeted vesicles exhibited limited association with PSMA-positive cells upon receptor blocking with the targeting antibody (0.1 AE 0.0% and 3.9 AE 3.7% for antibody-and urea-targeted vesicles, respectively).
The equilibrium binding affinity (K D ) was estimated from nonlinear regression curve fit analysis (0.97 < R 2 < 1) for the antibody-labeled vesicles (35.6 AE 1.5 mmol/L), the urea-based labeled vesicles (147 AE 9 mmol/L), and the radiolabeled antibody (22.9 AE 2.1 nmol/L; Supplementary Fig. S2A-S2C , respectively).
The average loading efficiency of 225 Ac in all targeted and nontargeted vesicles was 47.1 AE 16.6% (n ¼ 16). In the presence of cells, vesicles retained 78.5 AE 3.6% (n ¼ 16) of encapsulated radioactivity for the entire length of studies. The antibody radiolabeling efficiency was 3.4 AE 0.3% (n ¼ 2). Antibody radiolabeling was stable (86.3 AE 2.3% of radioactivity retained, n ¼ 2) for the length of the reported studies.
PSMA expression by HUVEC
HUVEC cells incubated with CCM on Matrigel expressed PSMA at significant levels (63 mean shift with respect to a shift of 3 for untreated cells, Supplementary Fig. S3A ; and positive staining by Western blot analysis, Supplementary Fig. S3B ) relative to the Fig. 1 and Supplementary  Table S2 .
stably PSMA-positive cell line LnCaP (255 mean shift) corresponding to a reported 1.8 Â 10 5 PSMA receptors per cell (17) . Because removal of CCM, upon completion of the initial 18-hour incubation period, resulted in decrease of PSMA expression by HUVEC over time ( Supplementary Fig. S4 ), all reported studies were performed in the presence of CCM to ensure stable PSMA expression. Finally, introduction of a flow field (at 15 s À1 shear rate) overlaying HUVEC decreased the PSMA expression in HUVEC by a factor of almost three relative to static culture conditions ( Supplementary Table S1 ).
Killing efficacy and cell-associated radioactivity delivered by different constructs
Specific cell association of delivered radioactivity significantly increased with incubation time for all targeted constructs (P < 0.01) and depended on incubation conditions (static and under flow; Supplementary Table S2 ). Both types of targeted vesicles delivered comparable radioactivities per cell with similar extents of internalization. For comparison, the 225 Ac-labeled antibody delivered significantly greater levels of radioactivity per cell relative to targeted vesicles at the longer incubation times (4 and 6 hours; P < 0.01).
Across all targeted constructs loaded with 225 Ac, viabilities of PSMA-positive HUVEC exhibited significant decrease with treatment time for each construct (P < 0.01; Fig. 1A and B ). Initiating the MTT assay after three doubling times resulted in approximately 5% to 10% reduced viability relative to performing the assay after only one doubling time (Supplementary Fig. S5 ; one doubling time of PSMA-positive HUVEC was 36 hours).
Both types of targeted vesicles (white and grey bars in Fig. 1A  and B ) resulted in significantly greater kill (P 0.002) of PSMApositive HUVEC compared with vesicles containing no targeting group (white bars with tilted pattern) at 6 hours of incubation ( Fig. 1C and D) , for both static and flow conditions. The observed cell kill mediated by both types of targeted vesicles should not be attributed to leaked radioactivity ( 225 Ac-DOTA at 7.4 kBq/mL or 20% of 37 kBq/mL; at 6 hours; P < 0.01; Fig. 1C -F). Vesicles loaded with 225 Ac and labeled with a nonspecific antibody (white bars with horizontal pattern in Fig. 1C and D) or with a nonactive urea analog (gray bars with horizontal pattern in Fig. 1C and D) affected cell viability similarly to the 225 Ac-loaded vesicles containing no targeting group (white bars with tilted pattern).
Selectivity in affecting the viability of PSMA-positive HUVEC (Fig. 1A and B ) relative to normal endothelium (PSMA-negative HUVEC; Fig. 1E and F) was indicated by the corresponding different cell viabilities (P 0.01) at 6 hours of incubation for all radiolabeled targeted constructs, and at 10 hours of incubation for the radiolabeled antibody ( Supplementary Table S3 ), both at the static and flow conditions.
On PSMA-negative HUVEC in static conditions, after one hour of incubation, Ab-targeted vesicles were more lethal than urea-targeted vesicles (P ¼ 0.007). This finding cannot be supported by different radioactivity uptake by cells ( Supplementary Table S2 ).
Interestingly, Fig. 2 (and Supplementary Fig. S6 ), which depicts the viability of cells (shown in Fig. 1) versus the corresponding uptake of radioactivity by cells (shown in Supplementary Table S2 as a function of time) for each of the constructs that were evaluated, shows that any level of associated radioactivity per cell resulted in greater killing efficacy when delivered by PSMAtargeting vesicles instead of the radiolabeled PSMA-targeting antibody. The presence of flow ( Supplementary Fig. S7 ) did not affect efficacy.
Intracellular localization of constructs
PSMA-positive HUVEC incubated with PSMA-targeting antibody-labeled (red) and urea-labeled (purple) vesicles (Fig. 3A , first and second plots, respectively) exhibited punctate fluorescence within the cytoplasm and in the case of the urea-targeted vesicles, a pronounced perinuclear localization. The PSMAtargeting antibody (Fig. 3A , third panel, green) localized mainly in the region closer to the plasma membrane far from the nuclear envelop. Quantitative processing of images of all constructs ( Fig. 3B ), in the absence and presence of inhibitors, support these observations. Chlorpromazine, an inhibitor of clathrin-mediated endocytosis, did not affect the cell uptake (Fig. 3A , thin continuous lines) and the intracellular spatial distributions (Fig. 3B ) of any construct. Genistein, an inhibitor of caveolae-mediated endocytosis, decreased the cell uptake of both types of targeted vesicles and of the antibody (Fig. 3A,  dashed lines) .
Presaturation of cells with the free PSMA antibody or the free lysine glutamate urea agent (Fig. 3C ) significantly decreased the association of all constructs with cells demonstrating PSMAspecific receptor-mediated uptake.
Discussion
The major finding of this study is that radionuclide carriers (and in particular targeted lipid vesicles) that promote localization of 225 Ac close to the cell nucleus, further enhance the already high killing efficacy of the delivered activity of a-particle emitters compared with radionuclide carriers that localize close to the cell's plasma membrane (such as radiolabeled antibodies). Nuclear localization has been extensively explored for very short range emitters (such as of Auger electrons; ref. 5), but not for a-particle emitters probably with the exception in the context of boron neutron capture therapy (18) and one study on using a modular transporter of astatine-211 (19) . We utilized lipid vesicles loaded with 225 Ac and labeled with a urea-based low-molecular-weight agent (11) and an antibody (20) , both targeting the PSMA on human endothelial cells. Both types of vesicles improve the killing efficacy of delivered activity per cell by almost 3-fold relative to the killing efficacy of the same levels of activity when delivered by the PSMA-targeting antibody (Fig. 2) . The increase in killing efficacy, which is also accompanied by increased levels of dsDNAs (beyond the arbitrary threshold shown by the red line, Fig. 4 ; ref. 21) , strongly correlates with intracellular patterns of vesicles exhibiting localization close to the cell nucleus, unlike the antibody which preferentially localizes near the plasma membrane during the period of observation (Fig. 3B ). Other nanoparticles, not necessarily lipid vesicles, may result in similar perinuclear trafficking (22) . The observed spatial intracellular distributions of vesicles are expected to result in an increase of the effective solid angle of the (at least first) emitted a-particle (from the carrier-associated parent nuclide) with respect to the nucleus increasing, therefore, the probability of its trajectory crossing the nucleus. An approximate dosimetric analysis using the MIRDcell.v2.0 software (23) supports the above claims ( Supplementary Table S4 for 225 Ac without daughters and Supplementary Table S5 for 225 Ac including radioactive daughters).
The choice of targeting ligand (in the sense of its role on altering the spatiotemporal intracellular distributions of the delivered nanoparticle) may affect the efficacy of nanoparticles as is suggested by a previous study on vesicles labeled with the PSMA targeting antibody J591 or the A10 aptamer (12) which demonstrated that only vesicles targeted with the J591 antibody perform similarly well as the radiolabeled antibody when compared in terms of radioactivity delivered per cell.
In the present studies, although the extent of endocytosis of both types of targeted vesicles and of the antibody is significantly decreased by the same inhibitor of caveolae-mediated endocytosis, their intracellular spatial distributions are dramatically dif-ferent ( Fig. 3B) suggesting the existence of potentially additional factors that govern the internalization mechanism(s) (22) .
To enable further development of targeted vesicles as carriers of 225 Ac against easily accessibly cells (e.g., neovasculature) with relatively low copies of targeted receptors, at least two aspects of their design should be improved: the apparent K D and the loading ratio of emitter to carrier. We have shown that the latter can in principle be improved by introducing greater radioactivity levels during loading which is equal to or greater than 47% of introduced radioactivity (for radioactivity levels up to at least 7.4 MBq). Decreasing the apparent K D of targeted vesicles may be enabled by potentially optimizing the conjugation density of targeting ligands on vesicles (24) or the size of nanoparticles (25) .
In summary, nanoconjugation of PSMA-targeting ligands using lipid vesicles loaded with 225 Ac improves the killing efficacy of delivered activity per cell by almost 3-fold relative to the killing efficacy of the same levels of activity per cell when delivered by the PSMA-targeting antibody. We attribute this finding to the perinuclear localization of the emitter when delivered by targeting vesicles that enhances the probability of emitted a-particles traversing through the cell nucleus.
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